Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"It is clear to me the only possible option the FDA gave IPIX was to study Brilacidin on the moderate to severe hospitalized covid patient"

You know that that's not how it works. The Company proposes the study design. The FDA would not refuse any Company the opportunity to run a well designed test of a treatment for mild to moderate covid sufferers. They certainly wouldn't have done that in the initial months of the pandemic.

An effective early stage therapeutic has been a goal for developers since the Spring of 2020. In its financial interest this Company could have directed its efforts toward "Covid drug studies on patients with the highest chance for success, patients with mild disease"...the low hanging fruit. And they decided against it.

Can you picture the conversation?
CEO: We have a drug that we feel would be effective in the treatment of sufferers in the early stage(s) of the disease.
FDA: Sorry but we're only approving trial designs for treatments targeting patients that are beyond that stage.


Simply ridiculous.